1. Immunology and Inflammation
  2. Microbiology and Infectious Disease

CRISPR-based functional genomics in human dendritic cells

  1. Marco Jost  Is a corresponding author
  2. Amy N Jacobson
  3. Jeffrey A Hussmann
  4. Giana Cirolia
  5. Michael A Fischbach  Is a corresponding author
  6. Jonathan S Weissman  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Stanford University, United States
  3. Chan Zuckerberg Biohub, United States
https://doi.org/10.7554/eLife.65856
Share this article
Cite this article
  1. Marco Jost
  2. Amy N Jacobson
  3. Jeffrey A Hussmann
  4. Giana Cirolia
  5. Michael A Fischbach
  6. Jonathan S Weissman
(2021)
CRISPR-based functional genomics in human dendritic cells
eLife 10:e65856.
https://doi.org/10.7554/eLife.65856
  2. Download BibTeX
  3. Download .RIS

Abstract

Dendritic cells (DCs) regulate processes ranging from antitumor and antiviral immunity to host-microbe communication at mucosal surfaces. It remains difficult, however, to genetically manipulate human DCs, limiting our ability to probe how DCs elicit specific immune responses. Here, we develop a CRISPR-Cas9 genome editing method for human monocyte-derived DCs (moDCs) that mediates knockouts with a median efficiency of >94% across >300 genes. Using this method, we perform genetic screens in moDCs, identifying mechanisms by which DCs tune responses to lipopolysaccharides from the human microbiome. In addition, we reveal donor-specific responses to lipopolysaccharides, underscoring the importance of assessing immune phenotypes in donor-derived cells, and identify candidate genes that control this specificity, highlighting the potential of our method to pinpoint determinants of inter-individual variation in immunity. Our work sets the stage for a systematic dissection of the immune signaling at the host-microbiome interface and for targeted engineering of DCs for neoantigen vaccination.

Data availability

Raw data from RNA-seq of unedited and edited moDCs are available at GEO under accession codes GSE161401 and GSE161466, respectively. Raw data from amplicon sequencing for all samples are available at SRA under accession code PRJNA673198. Processed data from amplicon sequencing as well as raw and processed data from the genetic screens are provided as supplemental files (Supplementary Files 2, 3, 4).

The following data sets were generated

Article and author information

Author details

  1. Marco Jost

    Cellular and Molecular Pharmacology / Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    For correspondence
    marco.jost@gmail.com
    Competing interests
    Marco Jost, MJ consults for Maze Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1369-4908

  2. Amy N Jacobson

    Department of Bioengineering / ChEM-H, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.

  3. Jeffrey A Hussmann

    Cellular and Molecular Pharmacology / Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Jeffrey A Hussmann, JAH consults for Tessera Therapeutics..

  4. Giana Cirolia

    NA, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.

  5. Michael A Fischbach

    Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States
    For correspondence
    fischbach@fischbachgroup.org
    Competing interests
    Michael A Fischbach, MAF is a co-founder and director of Federation Bio and Viralogic..

  6. Jonathan S Weissman

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    For correspondence
    Jonathan.Weissman@ucsf.edu
    Competing interests
    Jonathan S Weissman, JSW consults for and holds equity in KSQ Therapeutics, Maze Therapeutics, and Tenaya Therapeutics. JSW is a venture partner at 5AM Ventures and a member of the Amgen Scientific Advisory Board..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2445-670X

Funding

National Institutes of Health (K99 GM130964)

  • Marco Jost

Damon Runyon Cancer Research Foundation (DRG-2262-16)

  • Jeffrey A Hussmann

Howard Hughes Medical Institute (Investigator)

  • Jonathan S Weissman

National Institutes of Health (U01 CA217882)

  • Jonathan S Weissman

National Institutes of Health (DP1 DK113598)

  • Michael A Fischbach

National Institutes of Health (R01 DK11017404)

  • Michael A Fischbach

Chan-Zuckerberg Initiative

  • Jonathan S Weissman

Helmsley Foundation

  • Michael A Fischbach

Howard Hughes Medical Institute (Simons Faculty Scholar Award)

  • Michael A Fischbach

Burroughs Wellcome Fund (Investigators in the Pathogenesis of Infectious Disease program)

  • Michael A Fischbach

UCSF Program for Breakthrough Biomedical Research (Postdoctoral Independent Research Grant)

  • Marco Jost

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Jost et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,222
    views
  • 1,064
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marco Jost
  2. Amy N Jacobson
  3. Jeffrey A Hussmann
  4. Giana Cirolia
  5. Michael A Fischbach
  6. Jonathan S Weissman
(2021)
CRISPR-based functional genomics in human dendritic cells
eLife 10:e65856.
https://doi.org/10.7554/eLife.65856

Share this article

https://doi.org/10.7554/eLife.65856

Categories and tags

Research organism

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease

    SIV-specific neutralizing antibody induction following selection of a PI3K drive-attenuated nef variant

    Hiroyuki Yamamoto, Tetsuro Matano
    Research Article

    HIV and simian immunodeficiency virus (SIV) infections are known for impaired neutralizing antibody (NAb) responses. While sequential virus–host B cell interaction appears to be basally required for NAb induction, driver molecular signatures predisposing to NAb induction still remain largely unknown. Here we describe SIV-specific NAb induction following a virus–host interplay decreasing aberrant viral drive of phosphoinositide 3-kinase (PI3K). Screening of seventy difficult-to-neutralize SIVmac239-infected macaques found nine NAb-inducing animals, with seven selecting for a specific CD8+ T-cell escape mutation in viral nef before NAb induction. This Nef-G63E mutation reduced excess Nef interaction-mediated drive of B-cell maturation-limiting PI3K/mammalian target of rapamycin complex 2 (mTORC2). In vivo imaging cytometry depicted preferential Nef perturbation of cognate Envelope-specific B cells, suggestive of polarized contact-dependent Nef transfer and corroborating cognate B-cell maturation post-mutant selection up to NAb induction. Results collectively exemplify a NAb induction pattern extrinsically reciprocal to human PI3K gain-of-function antibody-dysregulating disease and indicate that harnessing the PI3K/mTORC2 axis may facilitate NAb induction against difficult-to-neutralize viruses including HIV/SIV.

    1. Immunology and Inflammation

    A VgrG2b fragment cleaved by caspase-11/4 promotes Pseudomonas aeruginosa infection through suppressing the NLRP3 inflammasome

    Yan Qian, Qiannv Liu ... Pengyan Xia
    Research Article

    The T6SS of Pseudomonas aeruginosa plays an essential role in the establishment of chronic infections. Inflammasome-mediated inflammatory cytokines are crucial for host defense against bacterial infections. We found that P. aeruginosa infection activates the non-canonical inflammasome in macrophages, yet it inhibits the downstream activation of the NLRP3 inflammasome. The VgrG2b of P. aeruginosa is recognized and cleaved by caspase-11, generating a free C-terminal fragment. The VgrG2b C-terminus can bind to NLRP3, inhibiting the activation of the NLRP3 inflammasome by rejecting NEK7 binding to NLRP3. Administration of a specific peptide that inhibits caspase-11 cleavage of VgrG2b significantly improves mouse survival during infection. Our discovery elucidates a mechanism by which P. aeruginosa inhibits host immune response, providing a new approach for the future clinical treatment of P. aeruginosa infections.

    1. Immunology and Inflammation
    2. Medicine

    Altered hepatic metabolism mediates sepsis preventive effects of reduced glucose supply in infected preterm newborns

    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.